INSIGHTS
July 1, 2026
The Hidden FDA Problems That Can Destroy Your Next Funding Round, Acquisition, or Exit
Congratulations. Your product is flying off shelves. Your social media team has mastered the algorithm. Investors are calling. The acquisition conversations have started.
You are exactly where every founder dreams of being.
And then diligence begins.
Suddenly, the questions are not just about revenue growth, margins, and customer acquisition costs. A buyer’s legal team starts asking:
“Can you prove this claim?”
“Is this ingredient legally marketed?”
“Show us your quality records.”
“Have you ever had an FDA inspection?”
“Have you received complaints or adverse events?”
Welcome to the regulatory portion of due diligence—the place where small compliance decisions can have very expensive consequences.
FDA Compliance Is Not Just About Avoiding a Warning Letter. It Is About Protecting Enterprise Value.
Private equity firms, strategic acquirers, and sophisticated investors understand that regulatory problems often come with a very expensive companion: uncertainty.
An unsupported health claim, an improper ingredient, a weak supplier qualification program, or a history of unresolved FDA observations may require significant remediation after closing.
And that can affect:
- Purchase price;
- Deal structure;
- Escrow requirements;
- Indemnification obligations;
- Closing timelines;
- Investor confidence.
In other words, your “minor compliance issue” may suddenly have a very large price tag attached to it.
The FDA Issues Buyers Look for During Due Diligence
Product Claims
For foods, beverages, dietary supplements, cosmetics, OTC drugs, and medical devices, product claims are often one of the first areas reviewed.
Buyers evaluate:
- Whether claims are adequately substantiated;
- Whether claims change a product’s regulatory classification;
- Whether marketing materials, websites, and social media contain problematic statements;
- Whether influencers or affiliates have made statements that create regulatory exposure.
A product does not become compliant simply because the marketing campaign generated ten million views.
Unfortunately, FDA does not hand out trophies for viral engagement.
Ingredients and Product Formulation
Sophisticated buyers evaluate whether ingredients are legally permitted for their intended use.
Potential concerns include:
- GRAS status;
- New dietary ingredient considerations;
- Cosmetic ingredient restrictions;
- OTC monograph compliance;
- Device component considerations.
A reformulation after a term sheet is signed is rarely anyone’s favorite business strategy.
Manufacturing and Supply Chain Risks
Regulators and investors alike expect companies to understand their supply chains.
Key diligence areas include:
- cGMP compliance;
- Supplier qualification;
- Testing programs;
- Quality systems;
- Foreign supplier oversight;
- Import history and FDA Import Alerts.
The Smartest Companies Prepare Before Buyers Ask
The best time to conduct an FDA regulatory health check is before the diligence request list arrives.
A proactive review allows companies to identify and remediate issues on their timeline—not during a high-pressure transaction where every delay creates leverage for the other side.
The Bottom Line
Great brands are built on innovation, consumer trust, and smart business decisions.
The most successful exits are built on those things plus something less glamorous but equally important: a strong regulatory foundation.
Companies preparing for investment, strategic partnerships, or acquisition should conduct an FDA regulatory diligence assessment early to identify risks, preserve valuation, and position themselves for a smoother transaction.